
Five Prime Therapeutics, Inc. Net Income 2011-2026 | FPRX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Five Prime Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -84.3 M | -137 M | -140 M | -150 M | -65.7 M | 250 M | -37.4 M | -28.9 M | -27.6 M | 19.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 M | -150 M | -40.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.12 | -0.36 % | $ 441 M | ||
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 8.32 | 3.67 % | $ 228 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 23.65 | 0.08 % | $ 3.01 B | ||
|
BioVie
BIVI
|
-17.5 M | $ 1.46 | 2.82 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
10.3 B | $ 91.44 | 0.29 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Burford Capital Limited
BUR
|
172 M | $ 4.52 | 9.18 % | $ 683 M | ||
|
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
-168 M | $ 3.1 | 4.56 % | $ 311 M | ||
|
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 3.17 | 1.44 % | $ 6.9 B | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
Catalyst Biosciences
CBIO
|
9.88 M | $ 19.48 | 0.39 % | $ 1.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | ||
|
Codexis
CDXS
|
-44 M | $ 1.95 | 6.87 % | $ 170 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-46.4 M | $ 3.01 | 0.67 % | $ 257 M | ||
|
Cerus Corporation
CERS
|
-15.6 M | $ 1.91 | 2.69 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
-220 M | $ 15.11 | 4.71 % | $ 910 M | ||
|
Coherus BioSciences
CHRS
|
168 M | $ 1.72 | -0.87 % | $ 201 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-16.6 M | $ 0.46 | -13.02 % | $ 5.27 M | ||
|
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
CNS Pharmaceuticals
CNSP
|
-15.9 M | $ 2.25 | -0.44 % | $ 998 K | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
214 M | $ 24.95 | 1.05 % | $ 3.05 B | ||
|
Celldex Therapeutics
CLDX
|
-259 M | $ 31.33 | 0.85 % | $ 2.08 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-78.5 M | $ 10.27 | 0.98 % | $ 137 M | ||
|
Cardiff Oncology
CRDF
|
-45.9 M | $ 1.6 | 1.27 % | $ 107 M | ||
|
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M |